文献速递结核与非结核分枝杆菌

AADAC 单核苷酸多态性与结核患者利福喷丁血浆浓度降低相关

Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

在 173 名接受利福喷丁治疗的成人结核试验参与者中,按自报种族分层并校正剂量、性别、食物和 HIV 合并感染后,黑人参与者 AADAC rs1803155 G 等位基因与利福喷丁 AUC0-24 降低相关;非黑人参与者中未观察到该关联。

要点

  • 黑人结核患者 AADAC rs1803155 G 等位基因与利福喷丁暴露降低相关。
  • 黑人中携带一个 G 等位基因者低于杀菌目标暴露的 OR 为 2.97(95%CI 1.16–7.58)。
  • 非黑人参与者中 AADAC rs1803155 与利福喷丁暴露无关联。

核心结论

  • 黑人参与者的利福喷丁暴露随 AADAC rs1803155 基因型变化,G 等位基因更可能与低于杀菌目标的利福喷丁暴露相关。

研究设计与样本

  • 研究纳入结核试验联盟治疗试验的 173 名成人参与者,按自报种族(黑人/非黑人)分层。
  • 采用协方差分析校正 SNP、利福喷丁剂量、性别、食物和 HIV 合并感染对利福喷丁 AUC0-24 的影响。

主要发现

  • 黑人参与者中,AADAC rs1803155 G 等位基因相对于 A 等位基因使利福喷丁最小二乘均值 AUC0-24 总体降低 -10.2%(Wald 检验 P=0.03;错误发现率 0.10)。
  • 黑人参与者中携带一个 AADAC rs1803155 G 等位基因者低于目标杀菌利福喷丁暴露的几率是携带 A 等位基因者的三倍(OR 2.97;95%CI 1.16–7.58)。
  • 黑人参与者中携带两个 G 等位基因者的 OR 更大。
  • 非黑人参与者中 AADAC rs1803155 SNP 与利福喷丁暴露无关联。
  • 黑人和非黑人参与者中,其他评估基因均与利福喷丁暴露无关联(P>0.05;错误发现率>0.10)。

临床怎么用

  • 在黑人结核患者中可关注 AADAC rs1803155 基因型,以识别利福喷丁暴露可能低于杀菌目标者。
  • 非黑人患者中 AADAC rs1803155 对利福喷丁暴露的关联未观察到,不宜直接外推。

局限性

  • 研究仅纳入治疗试验中的成人参与者,样本量 173 例。
  • 作者指出需进一步药物基因组学研究在不同患者群体中描述 AADAC rs1803155 与利福喷丁暴露不足的关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rifapentine exposure is associated with bactericidal activity against Mycobacterium tuberculosis, but high interindividual variation in plasma concentrations is encountered. OBJECTIVES: To investigate a genomic association with interindividual variation of rifapentine exposure, SNPs of six human genes involving rifamycin metabolism (AADAC, CES2), drug transport (SLCO1B1, SLCO1B3) and gene regulation (HNF4A, PXR) were evaluated. METHODS: We characterized these genes in 173 adult participants in treatment trials of the Tuberculosis Trials Consortium. Participants were stratified by self-identified race (black or non-black), and rifapentine AUC from 0 to 24 h (AUC0-24) was adjusted by analysis of covariance for SNPs, rifapentine dose, sex, food and HIV coinfection. This study was registered at ClinicalTrials.gov under identifier NCT01043575. RESULTS: The effect on rifapentine least squares mean AUC0-24 in black participants overall decreased by -10.2% for AADAC rs1803155 G versus A allele (Wald test: P = 0.03; false discovery rate, 0.10). Black participants with one G allele in AADAC rs1803155 were three times as likely to have below target bactericidal rifapentine exposure than black participants with the A allele (OR, 2.97; 95% CI: 1.16, 7.58). With two G alleles, the OR was greater. In non-black participants, AADAC rs1803155 SNP was not associated with rifapentine exposure. In both black and non-black participants, other evaluated genes were not associated with rifapentine exposure (P > 0.05; false discovery rate > 0.10). CONCLUSIONS: Rifapentine exposure in black participants varied with AADAC rs1803155 genotype and the G allele was more likely to be associated with below bactericidal target rifapentine exposure. Further pharmacogenomic study is needed to characterize the association of the AADAC rs1803155 with inadequate rifapentine exposure in different patient groups.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Weiner M, Gelfond J, Johnson-Pais TL, et al. Decreased plasma rifapentine concentrations associated with AADAC single nucleotide polymorphism in adults with tuberculosis. J Antimicrob Chemother. 2021. PMID: 33374006. doi:10.1093/jac/dkaa490

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。